CV

Biographical Data

Date of birth: 16 February 1982. Nationality: Spanish.

Languages

Spanish and Catalan: native, English: proficient user, French: independent user, Greek: independent user.

Education

• Master in Nutrition and Health (2021 – 2022)

Valencian International University (VIU), Valencia, Spain.

Subjects coursed: Physiology and metabolism of nutrition; Mediterranean diet and health; Nutrition and pathologies; Nutrition and food policies; Nutrition education and nutritional psychology; Nutrition and food in communities; Advances in nutrition and food. Master’s final project: Chrononutrition: prevention and treatment of metabolic health.

• EU official Master in Health Economics and Pharmacoeconomics (Feb 2016 – Jan 2018)

Universitat Pompeu Fabra and Barcelona School of Management (4^th internationally ranked in health economics). Term paper: Determinants linked to polypharmacy in Spanish old population. Prevention and intervention strategies to inappropriate prescribing in Spanish old population.

Led to project MINI-MED & NUTRI-BÉ presented to the Awards for Initiative and Business Capacity – UPF EMPREN EMPRESA – Call 2017

• Curso Superior Marketing Digital and Social Media (Nov 2016 – 32 hours)

Imagina Business School (IMA winner 2015), Barcelona, Spain.

• European PhD (Cum laude) and Postdoc in Life Sciences, inside the program of Organic Chemistry and Biochemistry Department, Chemoinformatics and Drug Design specialty in 2009 (Jul 2005 – Jun 2009)

Institut Químic de Sarria, Universitat Ramon Llull, Barcelona, Spain.

For fulfilment of European phD, 3 months research in Aberdeen University, Aberdeen, Scotland.

• Certificate of pedagogical competence, physics and chemistry specialities (Sep 2008 – May 2009)

Universitat de Barcelona, Barcelona, Spain.

• Patents and Utility Models (Fundamentals, Writing, Documentation modules) (Feb 2008 – 31 hours)

Centro de Patentes de la Universidad de Barcelona (UB) & Oficina Española de Patentes y Marcas (OEPM)

• DEA in Computational Chemistry (Sep 2006 – Sep 2007)

Institut Químic de Sarria, Universitat Ramon Llull, Barcelona, Spain.

• BSc in Engineering Chemistry (Sep 2000 –Jul 2006)

Institut Químic de Sarria, Universitat Ramon Llull, Barcelona, Spain.

• BSc in Organic Chemistry (Sep 2000 – Jun 2005)

Institut Químic de Sarria, Universitat Ramon Llull, Barcelona, Spain.

• Piano Teacher degree (Sep 1992 – Sep 2002)

Higher Music Conservatory of Barcelona (Liceo), Barcelona, Spain.

Experience and Fellows

Scientist (Product Chemistry and Manufacturing) , PQT/VCP, WHO HQ, Geneva (July 2023 –  )

Serve as the Prequalification/Vector Control Product Assessment team’s expert on the formulation and manufacturing of vector control products submitted to PQT for review, evaluation, and assessment.
Responsible for interacting with the PQT/VCP and the experts in product chemistry who are participants in the Assessors Group working with PQT/VCP to assess the applications and data dossiers submitted
to PQT for prequalification listing.
Collaborate with the expert assessors to prepare the product chemistry data review, product specification conclusions and chemical product profile for inclusion in the prequalification determination. Serve as the point of contact on all technical issues related to the product chemistry of a vector control product, including the Joint Meeting on Pesticide Specifications (JMPS) and coordinate regularly with relevant WHO Departments including the Control of Neglected Tropical Diseases (NTD) and the WHO Global Malaria Program (GMP), regulatory vector control authorities of member states, stakeholders and
vector control product manufacturers worldwide.

Programme Officer, COVAX, and PMO IVB, WHO HQ, Geneva (April 2022 – June 2023 )

Program Officer at Immunisation, Vaccines and Biologicals Department (IVB) and Governance and Coordination at the Strategic Coordination Office for COVAX, the global effort to vaccinate the world against COVID-19, responsible for convening pillar governance meetings, cross-WS visibility of issues decisions, PM and convening support of select cross-partner WS where tight and strategic cross-partner coordination needed (key activity areas include: Strategy , Manufacturing, External Communications, Resource Mobilization), stakeholder engagement and alignment leading to key strategic decisions for determining key strategic and operational priorities of COVAX.

WHO Technical Officer, Digital Health and Innovation Department, WHO HQ, Geneva (March 2020 – April 2022 )

Governance system, strategy, action plan, architecture blueprint for digital health systems and solutions. Establishing reference implementations, maturity models, validate interoperability and processes to ensure digital health technologies achieve positive health outcomes in short and long term. Facilitate the exchange and implementation of ideas, expertise and resources in the digital health arena while mitigating risks and ensuring equity in the access to the benefits of innovations and products to achieve the Triple Billion Goal and SDG3.

https://www.who.int/health-topics/digital-health#tab=tab_1

European Commission. DG CONNECT Dir H – Unit 3 – eHealth, Well-being, and Ageing. (November 2017 -March 2020)

Programme Officer, EU policies, and Research Coordination

GENERAL PROGRAM MANAGEMENT: Programme implementation

Preparation & implementation of H2020 activities: contribution to future work programmes, evaluation of proposals, management of projects throughout their whole life cycle,including collection and follow-up of deliverables, financial validations,amendments, audits,final evaluation,closing of projects, dissemination and use of project results. Impact assessment of H2020 framework programme and new Horizon Europe programme.

POLICY DEVELOPMENT: Policy and strategy development

Define and implement EC policy on health and care in the Digital Single Market,notably in the area of personalised medicine,data infrastructures and policies related to H2020 Societal Challenge 1″Health,demographic change and wellbeing”, Horizon Europe Health Cluster and Digital Europe Programme (2021-2025)

• Contribution to preparing the Declaration of Cooperation “Towards access to at least 1M sequenced genomes in the European Union by 2022” that was signed by Member States on Digital Day 2 (10th April 2018). Defining a Roadmap & Implementation Plan for establishing a European Health Data Infrastructure, including this signed Genomics declaration,is currently one of my responsibilities,and I am very enthusiastic of this great challenge.
• Defining the EC Strategy for AI for healthcare and European e-health Data Space for the 2020-2024.
• Defining and guiding the “Innovative Health Initiative” Industry Partnership (extended IMI) in relation to our EC Unit H3 policies.

COMMUNICATION and PUBLICATION: Dissemination relating to Programme, projects and EC health policies

Participation in internal and external workshops, meetings, conferences. Interaction and cooperation with relevant stakeholders.Evidence gathering.

• Manage and monitor calls for proposals and actively inform the research constituency and other Programme stakeholders. Notably calls related to public health policies, i.e. big data supporting public health policies. In charge of all the in silico medicine portfolio at CNECT/H3
• Manage and monitor the submission and evaluation of proposals (selection of experts, reporting) and the grant preparation process
• Monitor and assess the fulfillment of contractual obligations under the grant agreement as regards scientific aspects (including organizing checks and reviews, initiating audits and corrective measures, reporting), with the assistance of external experts (if needed) and with the assistance of internal financial and administrative staff
• Provide the necessary support to beneficiaries of EU grants as to maximise the likelihood of successful Programme implementation (technical achievement,dissemination,exploitation)
• Research strategy:FP9,Horizon Europe,DEP topic penholder & impact assessment
• Active role in development policies for establishing a European Health Data Infrastructure and the Genomics Declaration
• Support to the European Innovation Partnership on Active and Healthy Ageing, which has produced a state of the art methodology to address impact assessment of innovations
• IMI2 industry SGG member representing EC/CNECT
• Co-chair CNECT in PC meetings SC1 with MS
• Keynote speeches, round panels in conferences, workshops, networks, technology watch activities, courses

https://ec.europa.eu/digital-single-market/en/content/ehealth-well-being-and-ageing-unit-h3

Senior Researcher. Research Group on Systems Pharmacology. Research Program on Biomedical Informatics (GRIB). IMIM Hospital del Mar Medical Research Institute, Biomedical Research Park (PRBB), Barcelona, Spain (May 2017 –November 2017)

• • Senior researcher. Principal Investigator (Group Leader) of the research project awarded by the Ministry of Economy and Industry / Carlos III Health Institute associated with the 2016 call for the Strategic Health Action 2013 – 2016 (Ref: CP16 / 00088. Reducing Prescription Medicine Consumption in the Elderly “MINI-MED”)
  • Management of PhDs and post-doctorates
  • Management of research projects (scientific background, technical achievement, budget, dissemination, exploitation)
  • Drafting of journal papers and project proposals
  • Organization of international conferencesPrincipal Investigator (Group Leader) of the research project awarded by the Ministry of Economy and Industry / Carlos III Health Institute associated with the 2016 call for the Strategic Health Action 2013 – 2016 (Ref: CP16 / 00088. Reducing Prescription Medicine Consumption in the Elderly “MINI-MED”)
    

http://syspharm.imim.cat/

http://grib.imim.es/about-us/personal.html?lab=6

European Commission Scientific Research Administrative Trainee at DG Connect
Unit A1 – Robotics & Artificial Intelligence (March 2017 – July 2017)

• Participation in the annual impact assessment of the H2020 cPPPs (Contractual Public-Private Partnerships). This was an exercise leaded by DG RTD, which involved several DGs. My work consisted in collecting, processing and analysing data about the robotics PPP and the portfolio of robotics R&D projects managed by my unit.
• Project/programme management
• Contribute to the work of the unit through the application of my scientific and health economic competences and educational background.
• To acquire sound knowledge and practical experience of EU policies and missions, rules, procedures and activities of the Commission, especially in fields related to robotics and artificial intelligence.
• To participate in meetings at different levels and collaborate in organizational, information, documentation, administrative and logistic tasks of value for the service and for the trainee Duties: Retrieve, compile and analyse data related to the initiatives of the DG CONNECT unit -Robotics and AI-.
• Take an active part in the general work of the unit in order to gain familiarity with the unit interests, procedures and future prospects.
• Under the supervision and in agreement with the hierarchy to assist with dissemination and awareness activities on various media (paper, offline or online electronic media).
• Take part in the management of EC project’s life cycle, evaluations of proposals, selection criteria, eligibility, admissibility, chairing consensus meetings.

https://ec.europa.eu/digital-single-market/en/dg-connect

Medical writer. Kalispera medical writing (Sep 2016 – May 2017 )

• Design and layout of multimedia materials for dissemination of scientific content for the pharmaceutical industry.
• Responsible for designing the image and create digital materials. Creation of digital content, stylish, attractive, modern and maintaining the scientific rigor of texts created by clinicians.
• Scientific communication (video design, html, e-pub, newsletters, courses, posters, medical information letters, pharma cards, scientific journals, conference reviews of high quality content)
• Covering of conferences (i.e. CPhI international show daily journal or WoHiT)

http://violetaisabel-perez-nueno.com/category/medical-writing/

http://violetaisabel-perez-nueno.com/category/marketing-de-contenidos/

http://violetaisabel-perez-nueno.com/meeting-pepper-at-wohit/

Guest Editor: Current Pharmaceutical Design QSP Special Issue

http://www.kalispera.net/en

Senior Scientist. Lorraine Research Laboratory in Computer Science and its Applications (LORIA),Orpailleur Team,Vandoeuvre-lès-Nancy,France.IQS,URL,visiting scholar (Jul 2015 – Sep 2016)

https://www.inria.fr/en/centre/nancy

 http://violetaisabel-perez-nueno.com/loria/

Senior Scientist. Harmonic Pharma, Vandoeuvre-lès-Nancy, France (Jul 2012 – Jun 2015)

• Technology Assessment to provide Harmonic Pharma with the information needed to make technology investment decisions
• Software development – In charge of a group of engineers
• Management – Project management
• Development of chemoinformatic tools for polypharmacology purposes, drug repositioning, side effects prediction, and network pharmacology

http://www.harmonicpharma.com/en/core-technology/polypharmacology/

http://pubs.acs.org/doi/abs/10.1021/acs.jcim.5b00120

• Impact evaluation of the technology developed
• Innovation Management, Project Management

Project Proposals Elaboration, Scientific Writing and Communication

http://www.harmonicpharma.com/en/

• In charge of a group of engineers
• Awarded Research projects(Co&Investigator)

-2011-2015.“Evaluation of the antitumor activity of new identified drugs in various primary human cancer xenografts”. Institut Curie,Inserm U830,Harmonic Pharma

• Press Release Institut Curie – Harmonic Pharma anti-cancer activity collaboration (2012): http://harmonicpharma.com/wp-content/uploads/2015/03/CP-HPharma_IC_NOV2012_eng.pdf

Research Scientist. Lorraine Research Laboratory in Computer Science and its Applications (LORIA), Orpailleur Team, Vandoeuvre-lès-Nancy, France (Mar 2010 – Jun 2012)

PostDoctoral Fellow Marie Curie (2010), FP7-PEOPLE-2009-IEF.

2 years «Development of Virtual Screening Algorithms: Exploring Multiple Ligand

Binding Modes Using Spherical Harmonic Consensus Clustering» EC Grant agreement: 254128

http://cordis.europa.eu/result/rcn/59841_en.html

4 months research at IGMM-CNRS Team Tazi and Institut des Biomolécules Max Mousseron (IBMM), UMR 5247, Faculté de Pharmacie, Montpellier, (FRANCE).

http://www.ibmm.univ-montp1.fr/?Using-consensus-shape-clustering&lang=fr

PostDoctoral Fellow (2010), BE-DGR 2009-2n termini, Research outside Catalonia Grant, Catalan Parliament. 4 months Research at LORIA, Nancy, France: «Spherical harmonic shape matching for virtual screening». http://violetaisabel-perez-nueno.com/loria/

Research Scientist. Institut Químic de Sarria (IQS), Organic Chemistry Department, Grup d’Enginyeria Molecular (GEM), Universitat Ramon Llull, Barcelona, Spain (Jul 2005 – Jun 2009)

• PhD Thesis: «Virtual screening tools applied to HIV entry inhibitors. Design of novel anti-HIV compounds». Qualification: Cum laude http://www.tdx.cat/handle/10803/9311
• Graduate Fellow (2008),FI2008,Young researcher contract,Catalan Parliament,Barcelona,Spain

Graduate Fellow (2005), IQS, Ramon Llull University, Barcelona, Spain.

Teaching Experience

Associate Professor. Institut Químic de Sarria (IQS), Universitat Ramon Llull, Barcelona, Spain (Jul 2009 – Feb 2010)

Teaching Computational Chemistry course to last year undergraduate students.

Assistant Professor. Institut Químic de Sarria, Universitat Ramon Llull, Barcelona, Spain (Sep 2005 – Sep 2007)

Teaching Basic programming and numerical calculus courses to first year undergraduate students.

Management – Supervisor of MSc Research Projects and Internships

Jesus Planesas (2009-2010). Master Thesis: “Ligand-based and structure-based computational models for virtual screening VEGFR inhibitors using MOE”.

Elena Escubedo (2010-2011). Master Thesis: “Study of the comparative affinity of diverse abuse drugs with the nicotine receptors involved in the addiction”.

Management – Supervisor of PhD Students

Jesus Planesas (2010-2015). PhD Thesis: “Study and virtual screening of antiviral compounds (HIV). Study of the allosteric modulation of agonists and antagonists of the CXCR4. Qualification: Cum laude.

http://www.tdx.cat/handle/10803/312147

Management – Invited Member of Thesis Advisory Committees (TACs)

Member of the examining board for the Thesis “In silico methodologies for the design of functional foods that can prevent cardiovascular diseases”, Esther Sala Argüello. Universitat Rovira i Virgili. (March 2011).

Member of the examining board for the Thesis “Identification of natural products as antidiabetic agents using computer-aided drug design methods” Laura Guash Pamies. Universitat Rovira i Virgili. (Nov.2011).

External rapporteur for the Thesis “New simplified melatonin analogues” Alessia Carocci. Dipartimento di Farmacia-Scienze del Farmaco, Università degli Studi di Bari “Aldo Moro” (Jan.2016).

Scientific Prizes and Awards

2016: Health Economics Grant from UPF Barcelona School of Management for the Master in Health Economics and Pharmacoeconomics.

2012: Medicinal Chemistry Conference, Lanzarote, March 2-5. Best Overall Poster Content Award on  “Gaussian ensemble screening (GES): A new approach to polypharmacology and virtual screening”.

2011: EXPOQUIMIA I+D+i Award for the work in 4 JCIM papers, the “Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors”. ChemMedChem 2008, 3, 1549-1557, and the patent WO2008049950-A1.

2011: Honorary mention award in the XII Premio de Investigación Dr. Antonio Esteve for the work “Discovery of novel non-cyclam polynitrogenated CXCR4 coreceptor inhibitors”. ChemMedChem 2008, 3, 1549-1557.

2009: Grant awarded but not taken: Postdoctoral grant: Programa Talent-empresa (TEM) for contracting researchers (modality B: PhDs).

2009-2010: PhD Extraordinary Award from the Ramon Llull University inside the PhD program Chemistry and Engineering Chemistry, for the thesis “Virtual Screening Tools Applied to the Discovery of Novel HIV Entry Inhibitors”.

Contributions to Research Community – As Referee/Editor for International Journals

October 2016 Medical writer associated to Editor, Journal of the CPhi worldwide conference, 4-6 October 2016, Barcelona

http://viewer.zmags.com/publication/3f349b29#/3f349b29/4

http://viewer.zmags.com/publication/6bfe9969#/6bfe9969/4

http://viewer.zmags.com/publication/6bfe9969#/6bfe9969/6

2015-2016 Executive Guest Editor Current Pharmaceutical Design (IF: 3.452)

2009- Journal Referee: J. Chem. Inf. Model.; Eur. J. Med. Chem.; Journal of Open Access Bioinformatics; Peptides; Bioorg. & Med. Chem. Letters; Molecular Informatics; Molecular Biosystems; Anti-Cancer Agents in Med. Chem.; Curr. Top. Med. Chem.

Contributions to Research Community – As Program Committee / Steering Committee of Conferences

2015-2016: Steering Committee Member, 4th International Work-Conference on Bioinformatics and Biomedical Engineering (IWBBIO), Granada, Spain

2015-2016: ACS CINF Program Committee Member, ACS San Diego 2016, USA

2013: ACS CINF Program Committee Member, ACS Indianapolis 2013, USA

Contributions to Research Community – As Referee and Organizer for International Conferences

2016: Organization of the symposium “Using quantitative systems pharmacology for novel drug discovery: a ‘systems-level’ perspective to reduce toxicity and increase the therapeutic effect of drugs towards ‘precision medicine‘”, 4th International Work-Conference on Bioinformatics and Biomedical Engineering (IWBBIO), Granada, Spain.

2015: Organizer of the symposium ” Quantitative and Systems Pharmacology: Thinking in a wider “systems-level” context accelerates drug discovery and enlightens our understanding of drug action ” at the 3rd IWBBIO, Granada, Spain.

2014: Organizer of the symposium “Drug discovery: Computer models can predict side effect targets“, 10th International Conference Computational Methods in Sciences and Engineering (ICCMSE),Athens, Greece.

2013: Organization of the symposium “Computational Profiling and Repositioning as Promising New Ways of Drug Development” ACS CINF, Indianapolis, USA.

2011: Session Chair in the 3^rd International Conference on Drug Discovery & Therapy, February 2011, Dubai (UAE), Anti-Cancer Drug Discovery & Therapy/ Drug Delivery & Targeting Session.

Keynote speeches & chairing sessions/roundtable

2018-09-7 VPH Conference 2018. Addressing in silico medicine as a closer reality: complementing in vivo & in vitro tools by in silico technology & reduce/partially replace animal testing. Awareness of regulation of in silico methods & medical devices for in silico clinical trials.

2018-09-19 Personalised Medicine, Healthy Measures. Can value-based healthcare be implemented in Europe? How Personalised Medicine & patient outcomes can help. Panel discussions: Healthcare Financing based on Value & Outcomes-based Healthcare Systems. Patient data as fuel for PM to discuss the benefits-to patients, entrepreneurs, governments & society-of use of patient data for prescribing the right drugs for a patient, at the right doses,tailored for their specific genetic make-up for better outcomes while reducing costs.

2018-09-21 Meeting Representatives of the Signatories of the Declaration:‘Towards access to at least 1 million sequenced genomes in the European Union by 2022’.Landscape for genomic data/infrastructures in Europe.

2018-10-20 National Congress of Portuguese Pharmacies. Debate Healthcare financing, Innovation, Healthy living & Digital Health in the pharmacy community. E-health solutions in European Community Pharmacies. The Portuguese National Association of Pharmacies represents 95% of the Portuguese community pharmacies, between the most developed in Europe in matters concerning pharmaceutical policies.

2018-11-12 Health care X.0:digital technologies & creation of value. ISPOR. Panel. Potential of digital technologies in creating & delivering better value in healthcare. Opportunities for health economics & outcomes researchers to participate in co-creation of the “next healthcare system”. Discussion: Healthcare innovation, value & evidence-based medicine, managing & measuring impact of digital health technologies.

Scientific Management

Funding of research projects as Investigator

January 2017: Miguel Servet I funded project “Reducing Prescription Medicine Consumption in the Elderly” PI: Violeta I.Perez-Nueno. Project budget: €121.500; Period: 2016-2020.

November 2015: ERC Starting Grant Application Submitted, not successful. PI: Violeta I.Perez-Nueno.

Funding of research projects – Awarded as Co-Investigator

“Evaluation of the antitumor activity of new identified drugs in various primary human cancer xenografts”. Institut Curie (1), Inserm U830 (2), and Harmonic Pharma (3). Period: 2011-2015.

Investigators: Dr Didier DECAUDIN (1), Dr Elisabetta MARANGONI (1), Dr Fariba Némati (1), Mrs Ludmilla DE PLATER (1), Drs Thierry DUBOIS (1), Charles DECRAENE (1), Marc-Henri STERN (2), Dr Michel SOUCHET(3), Dr Arnaud Sinan KARABOGA (3), Dr Violeta I. PEREZ-NUENO (3)

http://www.ala.com/common/uploads/documents/news-132-121105-curie-cancer_harmonic-pharma-en.pdf

Other Research Projects in which I participated as Investigator

“Antiviral VIH-VHC research program: design and synthesis of potential antivirals”. Financing institution: MEDU – Ministerio de Educación y Ciencia; Contract: SAF2010-21617-C02-02; Subproject computational part budget: 65.000 €; PI: José Ignacio Borrell Bilbao; Period: 2010-2013.

“Design and selection of novel high performance nucleus in the research of new drugs for the vascular system”. Financing institution: CIDEM; Subcontract computational part budget €22.000; PI Josep Castells i Boliart; Period: 2009-2011.

“Design and synthesis of novel HIV inhibitors – ENTRINHIV-1”. Program: NBME – Programa Nacional de Biomedicina; Financing institution: MEDU – Ministerio de Educación y Ciencia; Contract: SAF2007-63622-C02-01; PI: José Ignacio Borrell Bilbao; Total budget: €96.800,00; Period: 2007- 2010.

“Design, synthesis and evaluation of the antiviral activity of novel anti-HIV compounds”. Financing institution: Fundació La Marató de TV3; Project: 020930; PI: Jordi Teixidó Closa, José Andrés Esté, Josefa Mallol; Total budget: €309.336; Period: 2001-2003.

Coursework/Workshops/Relation with stakeholders and evidence gathering.

• Communicating science to policy makers. Feeding policy <->research – – Keynote speeches & chairing session/roundtable (Author):

– Opening keynote speech ““Digital Transformation of Health and Care empowering citizens and building a healthier society”,”, substituting HoU,Brussels, Digital Health Single Market Conference: EC WORKSHOP ON SMART BIOELECTRONIC AND WEARABLE ELECTRONICS, 23/10/2019. Interaction with key stakeholders from industry

-Opening keynote speech “Artificial Intelligence for better Health and Care in the EU”, AI & health conference, Oslo, 15-17/09/2019

-Personalised Medicine 2018,Healthy Measures.Can value-based healthcare be implemented in Europe? How PM & patient outcomes can help

-NPCC 2018.Healthcare financing,Innovation,Healthy living& Digital Health in the pharmacy community

-ISPOR 2018.Health care X.0:digital technologies & creation of value.Panel.Potential of digital technologies in creating &delivering better value in healthcare.Health economics & co-creation of the “next healthcare system”

– Keynote speech, In silico opportunities in H2020, VPH conference, 5-6/09/2018

• Interaction with key stakeholders (Keynote speeches, round panels in conferences, workshops, networks, technology watch activities, courses) :

– SC1 programme commitee meetings with representatives of Member States (NCP), responsible for DG CNECT 10/4/2019, 16/09/2019, 12/12/2019 moved to 23/1/2020

– Helping in preparation, organization, and attendance to 7 Genomics Meetings with Signatory Member states of the Declaration and 2 Genomics meetings with high level experts, Brussels

– Steering Governing Group IMI F2F meetings attendance and assistance in preparation, 11/10/2019, 18-19/2/2019

– Preparation and attendance for DG CNECT of the R&I days, Brussels , 24-26/09/2019

– Health Infrastructures workshop, in collaboration with RTD, 14/10/2019

– Human Cell Atlas meetings, EC Assistance organizing in collaboration with RTD, Brussels, 7/2/2018, 14/1/2020

– Big Data Europe workshop, EC Assistance organizing in collaboration with RTD, 13/12/2018

– Health data research & European infraestructures.EC Assistance organizing,2018

– RTD Europe. EC Assistance organizing,2018

– Strategic priorities and Impact of Health/Biomedical Research for Society & Towards Health Research Cloud innovation Workshops.EC Assistance organizing,2018

– Insilico workshop.EC Co-organizer,2017

Attendance:

WoHiT World of Health IT, November 2016, Barcelona (Spain).

The “REACH” Regulation (Registration, Evaluation, and Authorization of Chemicals). Technical Conference, 2009, Barcelona (Spain).

Schrödinger workshop, 2009, Barcelona (Spain).

Discovery Studio 1.7, 2006, Barcelona (Spain).

Gaussian Workshop, 2006, Barcelona (Spain).

Tripos Training Course, 2007, Barcelona (Spain).

Folding and assembly of synthetic biomimetic nanomolecules, 2008, Barcelona (Spain).

Getting the most from biomolecular simulations: a practical workshop, 2008, Barcelona (Spain).

MOE Training Course, 2009, Barcelona (Spain).

Schrödinger workshop, 2009, Barcelona (Spain).

Work environment and computational chemistry tools at CESCA. Course, 2009, Barcelona (Spain).

Economical, medical and societal transfer

Technology transfer of the new and fast polypharmacology tool, Gaussian Ensemble Screening (GES), developed during FP7 Marie Curie (http://cordis.europa.eu/result/rcn/59841_en.html) to Harmonic Pharma SAS (http://www.harmonicpharma.com/core-technology/polypharmacology/). Exploitation of this technology into the cancer field led to the patent EP14305 487.2 – 1464.

Consensus shape algorithm developed during the PhD commercialized inside ParaFit^TM from the industrial package Cepos InSilico 2010 (http://www.ceposinsilico.de/company/news.htm)

International Scientific Visits

Aberdeen University (Aberdeen, UK) – visit (13 May 2007 to 18 August 2007). [LETTER]

Institut des Biomolécules Max Mousseron (IBMM), Faculté de Pharmacie, (Montpellier,France)-1^st speaker visit (24 November 2011) – 2^nd visit (December 2011 – March 2011). [SPEAKER VISIT]

Institut Génétique Moléculaire Montpellier (IGMM-CNRS) Team Tazi, (Montpellier, France) – visit (September 2011 – November 2011) [LETTER][ATTESTATION]

Biotecnología Habana (La Havana, Cuba)– visit (8^th – 11^th December) [LETTER]

Other visits: Seminars

-2016 July, Seminar 18/07/2016, “Spherical harmonics shape representations and drug repositioning” Bionext, Strasbourg, France

-2015 Université Paris Diderot – Inserm UMR-S 973. Molécules Thérapeutiques in silico (MTi) (Paris, France) – 1^st speaker visit (24 September 2015). 2^nd visit (19 November 2015).

– 2012 March,Seminar, Institute for Research in Biomedicine-Barcelona Science Park (IRB), Barcelona, Spain

– 2011 October,Lecture in Master Chemoinformatics “In silico drug design”,Faculté Chimie,Strasbourg,France

– 2010,2011,2012 March,Lecture in Master “Introduction to the process of drug discovery”, IUCT, BCN, Spain

– 2010 November, Chemoinformatics seminar, Inst. Munic. d’Investigació Mèdica (IMIM), Barcelona, Spain

– 2009 January, Seminar BINGO, Lorraine Research Lab Comput. Scie. and its App. (LORIA), Nancy, France

Media Coverage of Research Findings

Press Release Institut Curie – Harmonic Pharma anti-cancer activity collaboration (2012): http://www.ala.com/common/uploads/documents/news-132-121105-curie-cancer_harmonic-pharma-en.pdf

Cordis Europe, FP7-PEOPLE-2009-IEF (2012): http://cordis.europa.eu/result/rcn/59841_en.html

IQS –GEM Television TV3 (2006): Una nova família de fàrmacs lluitarà contra el càncer amb làser

Expoquimia(2011):http://www.clipmedia.net/GALERA/IQS/NdP/2011/101911_expoquimia/index_es.html

Teraflop Press HIV GEM IQS (2007): https://violeta-perez-nueno.000webhostapp.com/pdf/TF94%20Avenços.pdf

Cover Illustrations: JCIM 2008 48:3; JCIM 2014 54:3; JCIM 2015 55:9; contribution to JCIM 2015 55:1. http://pubs.acs.org/action/showCoverGallery?coverPage=1&journalCode=jcisd8

Computer skills

PressDatabase MySQL Basic knowledge;Database Access Basic knowledge; Presentation software MS PowerPoint Advanced knowledge; Programming languages VBA Basic knowledge; Programming languages C++ Working knowledge; Programming tools Eclipse Basic knowledge; Spreadsheet MS Excel Advanced knowledge; Statistical analysis software R Working knowledge; Website creation & management HTML Basic knowledge; Word processing MS Word Advanced knowledge; OS Mac,Windows,Unix,Linux Working knowledge;Digital communication,web & social media management at Kalispera S.L. (Hootsuite,Mailchimp,image databanks,digital strategic plan tools & software) Advanced knowledge

Scientific software

Chemoinformatics (i.e AMBER,Gaussian,MOE,Autodock…)

Statistical (i.e R,Stata)

Microsoft Suite

Graphical design & layout (InDesign,Articulate, social media programmatic calendar)

CV Summary

Worked at European Institutions.

Worked managing projects, digital market and social media.

27 peer-reviewed papers, of which 16 are as first author, 15 as corresponding author, 5 as second author, 1 as middle author.  1 book chapter and 1 Editorial . 2 patents

Restricted to papers in which I am first, second or corresponding author: h-index = 16.

Educated & trained in two global academic institutions from two different countries (UK, Spain). Two major scholarships awarded in this period (URL University, Catalan Parliament Contract).

Postdoctoral positions in two additional global academic institutions. Two independent research fellowships awarded in this period (FP7 Marie Curie, Catalan Parliament Outside Catalonia Postdoc).

Multiple awards and distinctions throughout education, research training and career. Member of several learned societies. Some works have appeared as front covers in international leading ACS journals or have received media attention (Institut Curie – Harmonic Pharma anti-cancer activity collaboration).

Already attracted substantial funding as co-investigator in Pharma Company.

International scientific visits to 11 research institutions in academia and industry: Aberdeen (University), Montpellier (IGMM-CNRS, IBBM), Strasbourg (University/Company), Nancy (LORIA), Paris (Paris-Diderot University), Barcelona (IUCT, IMIM, IRB, IQS).

48 international conference presentations (of which 17 invited talks and 17 poster presentations).

Commercialisation activities: two patents and research contracts.

Acted as referee for 17 international journals/conferences. Journal guest editor.

Session chair & 4 international symposia organization (ICDDT, ACS, ICCMSE, IWBBIO).

Already experience in teaching and supervising research students as university associate professor.

Currently working on several national and international collaborations (France, UK, Italy, Spain).